Nanobac Operating Cycle from 2010 to 2026
| NNBP Stock | USD 0.0001 0.00 0.00% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 267.95 | Current Value 281.35 | Quarterly Volatility 57.71006335 |
Check Nanobac Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nanobac Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 2.6 M or Total Revenue of 15.1 K, as well as many indicators such as Price To Sales Ratio of 90.9, Dividend Yield of 0.0 or Days Sales Outstanding of 56.52. Nanobac financial statements analysis is a perfect complement when working with Nanobac Pharmaceuticals Valuation or Volatility modules.
Nanobac | Operating Cycle | Build AI portfolio with Nanobac Stock |
Evaluating Nanobac Pharmaceuticals's Operating Cycle across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Nanobac Pharmaceuticals Incorporated's fundamental strength.
Latest Nanobac Pharmaceuticals' Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of Nanobac Pharmaceuticals Incorporated over the last few years. It is Nanobac Pharmaceuticals' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nanobac Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
Nanobac Operating Cycle Regression Statistics
| Arithmetic Mean | 280.98 | |
| Geometric Mean | 268.17 | |
| Coefficient Of Variation | 20.54 | |
| Mean Deviation | 27.63 | |
| Median | 297.73 | |
| Standard Deviation | 57.71 | |
| Sample Variance | 3,330 | |
| Range | 239 | |
| R-Value | 0.34 | |
| Mean Square Error | 3,150 | |
| R-Squared | 0.11 | |
| Significance | 0.19 | |
| Slope | 3.85 | |
| Total Sum of Squares | 53,287 |
Nanobac Operating Cycle History
About Nanobac Pharmaceuticals Financial Statements
Nanobac Pharmaceuticals shareholders use historical fundamental indicators, such as Operating Cycle, to determine how well the company is positioned to perform in the future. Although Nanobac Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Nanobac Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Nanobac Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 267.95 | 281.35 |
Pair Trading with Nanobac Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nanobac Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nanobac Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Nanobac Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nanobac Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nanobac Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nanobac Pharmaceuticals Incorporated to buy it.
The correlation of Nanobac Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nanobac Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nanobac Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nanobac Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Nanobac Stock Analysis
When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.